CANSINOBIO (06185) has announced that its recombinant trivalent poliomyelitis vaccine, utilizing Sf-RVN cells, has obtained approval from China's National Medical Products Administration to initiate clinical trials. This vaccine, crafted through sophisticated protein structure design and virus-like particle (VLP) assembly technology, eliminates viral genetic material entirely and operates independently of live viruses during both production and testing phases. Such features are anticipated to deliver exceptional safety and robust immunogenicity. Notably, the non-infectious VLP-based polio vaccine stands endorsed by the World Health Organization as a premier choice for future polio eradication efforts, positioning it as a potentially ideal solution for the disease's global elimination.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。